Seagen Inc
NASDAQ:SGEN
Intrinsic Value
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. [ Read More ]
The intrinsic value of one SGEN stock under the Base Case scenario is 143.78 USD. Compared to the current market price of 228.74 USD, Seagen Inc is Overvalued by 37%.
Valuation Backtest
Seagen Inc
Run backtest to discover the historical profit from buying and selling SGEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Seagen Inc
Current Assets | 2.6B |
Cash & Short-Term Investments | 1.2B |
Receivables | 631.6m |
Other Current Assets | 683m |
Non-Current Assets | 1.1B |
PP&E | 487.7m |
Intangibles | 495m |
Other Non-Current Assets | 100m |
Current Liabilities | 954.7m |
Accounts Payable | 224.8m |
Accrued Liabilities | 729.9m |
Non-Current Liabilities | 129.1m |
Other Non-Current Liabilities | 129.1m |
Earnings Waterfall
Seagen Inc
Revenue
|
2.3B
USD
|
Cost of Revenue
|
-566.1m
USD
|
Gross Profit
|
1.7B
USD
|
Operating Expenses
|
-2.5B
USD
|
Operating Income
|
-750.5m
USD
|
Other Expenses
|
300k
USD
|
Net Income
|
-750.2m
USD
|
Free Cash Flow Analysis
Seagen Inc
SGEN Profitability Score
Profitability Due Diligence
Seagen Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Seagen Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
SGEN Solvency Score
Solvency Due Diligence
Seagen Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Seagen Inc's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SGEN Price Targets Summary
Seagen Inc
According to Wall Street analysts, the average 1-year price target for SGEN is 229 USD .
Ownership
SGEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SGEN Price
Seagen Inc
Average Annual Return | 35.81% |
Standard Deviation of Annual Returns | 37.12% |
Max Drawdown | -14% |
Market Capitalization | 43.1B USD |
Shares Outstanding | 188 663 008 |
Percentage of Shares Shorted | 6.79% |
SGEN News
Last Important Events
Seagen Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Seagen Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. The company is headquartered in Bothell, Washington and currently employs 2,675 full-time employees. The company went IPO on 2001-03-07. The firm is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The firm is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The firm also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The firm's approved medicines include ADCETRIS, PADCEV and TUKYSA.
Contact
IPO
Employees
Officers
The intrinsic value of one SGEN stock under the Base Case scenario is 143.78 USD.
Compared to the current market price of 228.74 USD, Seagen Inc is Overvalued by 37%.